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Follicular lymphoma (FL) is a mature B-cell neoplasm
resulting from the transformation of germinal center (GC)
B-cells in secondary lymphoid organs. The acquisition of
the t(14;18) chromosomal translocation (giving rise to a
BCL2/IGH fusion and ectopic expression of the BCL2
proto-oncogene) constitute both a genetic hallmark and
the critical early event in the natural history of FL [1].
However, as t(14;18) is detectable at low frequency (<1 per
million B-cells) in up to 70% of healthy people, the rela-
tionship between t(14;18) and progression to disease
remains unclear [2]. To date, the available data supports a
multi-hit model of oncogenesis, where the stepwise acqui-
sition of synergistic oncogenic events is required for full
malignant transformation. The recent demonstration that
memory B-cells can re-enter GCs and participate to new
rounds of GC reactions has opened the possibility that
multi-hit B-cell lymphomagenesis gradually occurs
throughout life during successive immunological chal-
lenges[3-5]. Here we provide evidence for this scenario in
FL using a sporadic BCL2tracer mouse model mimicking
FL’s hallmark t(14;18) translocation, combined with mole-
cular/immunofluorescent tracking of t(14;18)+ clones and
normal memory B-cells in paired lymphoid tissue samples
from healthy individuals.
We show that BCL2-expressing memory B-cells require
multiple GC transits to acquire the distinctive FL-like
maturation arrest as GC B-cells with constitutive activa-
tion-induced cytidine deaminase activity, and to progress
to advanced precursor stages.
This protracted process of GC co-opting, accumulating
with age, would drive the major and early dissemination/
progression of t(14;18)+ precursors observed in remote
lymphoid tissues, including bone marrow, shaping the sys-
temic disease presentation observed in most patients.
Altogether, our data argue for a model of lymphomagen-
esis, in which progression to FL occurs asymptomatically
over an extended period of time, by subverting the
dynamic and plastic attributes of memory B-cells.
Our characterization of the pre-clinical phases driving
FL development in asymptomatic patients should help
rationalize prospective approaches designed to identify
biomarkers of risk, and innovative therapeutic targets
present in early, potentially more curable phases of the
disease.
Author details
1Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université,
Marseille, France. 2INSERM U1104, Marseille, France. 3CNRS UMR7280,
Marseille, France.
Published: 28 November 2012
References
1. Shaffer AL III, Young RM, Staudt LM: Pathogenesis of human B cell
lymphomas. Annu Rev Immunol 2012, 30:565-610.
2. Roulland S, Faroudi M, Mamessier E, Sungalee S, Salles G, Nadel B: Early
steps of follicular lymphoma pathogenesis. Adv Immunol 2011, 111:1-46.
3. Victora GD, Schwickert TA, Fooksman DR, Kamphorst AO, Meyer-
Hermann M, Dustin ML, Nussenzweig MC: Germinal center dynamics
revealed by multiphoton microscopy with a photoactivatable
fluorescent reporter. Cell 2010, 143:592-605.
4. Dogan I, Bertocci B, Vilmont V, Delbos F, Megret J, Storck S, Reynaud CA,
Weill JC: Multiple layers of B cell memory with different effector
functions. Nature Immunology 2009, 10:1292-1299.
5. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK: Different B cell
populations mediate early and late memory during an endogenous
immune response. Science 2011, 331:1203-1207.
doi:10.1186/1479-5876-10-S3-I10
Cite this article as: Roulland: Follicular lymphomagenesis: early steps
and associated risk factors. Journal of Translational Medicine 2012 10
(Suppl 3):I10.
1Centre d’Immunologie de Marseille-Luminy, Aix-Marseille Université,
Marseille, France
Full list of author information is available at the end of the article
Roulland Journal of Translational Medicine 2012, 10(Suppl 3):I10
http://www.translational-medicine.com/content/10/S3/I10
© 2012 Roulland; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
